nach oben

Pathology & Oncology Research

Erschienen in:

01.09.2011 | Research

The Evaluation of CD99 Immunoreactivity and EWS/FLI1 Translocation by Fluorescence in situ Hybridization in Central PNETs and Ewing’s Sarcoma Family of Tumors

verfasst von: Çiğdem Vural, Ömer Uluoğlu, Nalan Akyürek, Aynur Oğuz, Ceyda Karadeniz

Erschienen in: Pathology & Oncology Research | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Abstract

Ewing’s sarcoma family of tumors (ESFTs) are indicated by malignant, small, round and blue cell tumors of the bone and soft tissue. Gene rearrangements between EWS gene on chromosome 22q12 and members of the ETS gene family are common in and specific to ESFTs. Another defining characteristic of ESFTs is their membranous expression of the CD99. In contrast, such translocations and immunoreactivity are not found in central primitive neuroectodermal tumors (cPNETs). The aim of this study was to investigate the detection of EWS/FLI1 translocations and CD99 immunoreactivity in order to evaluate their clinicopathological features and their roles in the differential diagnosis of these tumors. In this study, we investigated CD99 immunoreactivity using immunohistochemistry and Ewing’s sarcoma / Friend leukaemia virus integration 1 (EWS/FLI1) translocation using the fluorescence in situ hybridization (FISH) method in 23 cases. CD99 expression was detected in 10/11 (90%) ESFT cases and 2/7 cPNET cases. In 18 cases EWS/FLI1 translocation was examined using the FISH method. The EWS/FLI1 translocations were detected in 7/8 (87.5%) ESFTs cases, whereas non of 8 cPNET cases were detected with this translocation. One case could not be classified as either central or peripheral, showed EWS/FLI1 translocation. There was a statistically significant difference in CD99 expression (p = 0.0013) and EWS/FLI1 translocation (p = 0,002) between cPNETs and ESFTs cases. In conclusion, CD99 expression and EWS/FLI1 translocation are specific and sensitive markers in the diagnosis of ESFTs. However, these were often not found in cases of cPNET. Therefore, in the diagnosis of ESFTs, clinical, radiological, histopathological and immunohistochemical parameters should always be evaluated together.

Furuno Y, Nishimura S, Kamiyama H et al (2008) Intracranial peripheral-type primitive neuroectodermal tumor-case report. Neurol Med Chir (Tokyo) 48(2):72–76CrossRef

McLendon RE, Judkins AR, Eberhart CG et al (2007) Central nervous system primitive neuroectodermal tumours. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds) WHO classification of tumours of the central nervous system, 4th edn. IARC, Lyon

Weiss SW, Goldblum JR (2008) Ewing’s sarcoma/PNET tumor family and related lesions. In: Schmitt W, Black S (eds) Enzinger & weiss’s soft tissue tumors, 5th edn. Mosby Elsevier, Philadelphia

Folpe AL, Goldblum JR, Rubin BP et al (2005) Morphologic and immunophenotypic diversity in Ewing family tumors: a study of 66 genetically confirmed cases. Am J Surg Pathol 29(8):1025–1033PubMed

Kontny U (2006) Regulation of apoptosis and proliferation in ewing’s sarcoma-oppotunities for targeted therapy. Hematol Oncol 24(1):14–21PubMedCrossRef

O’Sullivan MJ, Perlman EJ, Furman J et al (2001) Visceral primitive peripheral neuroectodermal tumors: a clinicopathologic and molecular study. Hum Pathol 32(10):1109–1115PubMedCrossRef

Ushigome S, Machinami R, Sorensen PH (2002) Chapter 14: Ewing sarcoma/primitive neuroectodermal tumor. In: Fletcher CDM, Unni KK, Mertens F (eds) World health organization classification of tumors: pathology& genetics of tumours of soft tissue and bone. IARC Press, Lyon

Llombart-Bosch A, Navarro S (2001) Immunohistochemical detection of EWS and FLI-1 proteins in ewing sarcoma and primitive neuroectodermal tumors: comparative analysis with CD99 (MIC-2) expression. Appl Immunohistochem Mol Morphol 9(3):255–260PubMedCrossRef

Mobley BC, Roulston D, Shah GV et al (2006) Peripheral primitive neuroectodermal tumor/ewing’s sarcoma of the craniospinal vault: case reports and review. Hum Pathol 37(7):845–853PubMedCrossRef

10.

Khoury JD (2005) Ewing sarcoma family of tumors. Adv Anat Pathol 12(4):212–220PubMedCrossRef

11.

Amiel A, Ohali A, Fejgin M et al (2003) Molecular cytogenetic parameters in ewing sarcoma. Cancer Genet Cytogenet 140(2):107–112PubMedCrossRef

12.

Folpe AL, Hill CE, Parham DM et al (2000) Immunohistochemical detection of FLI-1 protein expression: a study of 132 round cell tumors with emphasis on CD99-positive mimics of ewing’s sarcoma/primitive neuroectodermal tumor. Am J Surg Pathol 24(12):1657–1662PubMedCrossRef

13.

Gardner LJ, Ayala AG, Monforte HL et al (2004) Ewing sarcoma/peripheral primitive neuroectodermal tumor adult abdominal tumors with an ewing sarcoma gene rearrangement demonstrated by fluorescence in situ hybridization in paraffin sections. Appl İmmunohistochem Mol Morphol 12(2):160–165PubMedCrossRef

14.

Hadfield MG, Quezado MM, Williams RL et al (2000) Ewing’s family of tumors involving structures related to the central nervous system: a review. Pediatr Dev Pathol 3(3):203–210PubMedCrossRef

15.

Mhawech-Fauceglia P, Hermann F, Penetrante R et al (2006) Diagnostic utility of FLI-1 monoclonal antibody and dual-colour, break-apart probe fluorescence in situ (FISH) analysis in ewing’s sarcoma/primitive neuroectodermal tumour (EWS/PNET): a comparative study with CD99 and FLI-1 polyclonal antibodies. Histopathology 49(6):569–575PubMedCrossRef

16.

Mazur MA, Gururangan S, Bridge JA et al (1999) Intracranial ewing sarcoma. Pediatr Blood Cancer 45(6):850–856CrossRef

17.

Cohn SL (1999) Diagnosis and classification of the small round cell tumors of childhood. Am J Pathol 155(1):11–15PubMedCrossRef

18.

Devoe K, Weidner N (2000) Immunohistochemistry of small round-cell tumors. Semin Diagn Pathol 17(3):216–224PubMed

19.

Hasegawa SL, Davison JM, Rutten A et al (1998) Primary cutaneous ewing’s sarcoma: immunophenotypic and molecular cytogenetic evaluation of five cases. Am J Surg Pathol 22(3):310–318PubMedCrossRef

20.

Sheaff M, McManus A, Scheimberg I et al (1997) Primitive neuroectodermal tumor of the kidney confirmed by fluorescence in situ hybridization. Am J Surg Pathol 21(4):461–468PubMedCrossRef

21.

Pekala JS, Gururangan S, Provenzale JM et al (2006) Central nervous system extraosseous ewing sarcoma: radiologic manifestations of this newly defined pathologic entity. Am J Neuroradiol 27(3):580–583PubMed

22.

Kazmi SA, Perry A, Pressey JG et al (2007) Primary ewing sarcoma of the brain a case report and literature review. Diagn Mol Pathol 16(2):108–111PubMedCrossRef

23.

Kampman WA, Kros JM, De Jong THR et al (2006) Primitive neuroectodermal tumors (PNETs) located in the spinal canal: the relevance of classification as central or peripheral PNET, case report of a primary spinal PNET occurence with a critical literature review. J Neurooncol 77(1):65–72PubMedCrossRef

24.

D’ Antonio A, Caleo A, Garcia JF et al (2004) Primary peripheral PNET/ewing’s sarcoma of the dura with FISH analysis. Histopathology 45(6):642–656CrossRef

25.

Ishii N, Hiraga H, Sawamura Y et al (2001) Alternative EWS-FLI1 fusion gene and MIC2 expression in peripheral and central primitive neuroectodermal tumors. Neuropathology 21(1):40–44PubMedCrossRef

26.

De Alava E, Gerald WL (2000) Molecular biology of the ewing’s sarcoma/primitive neuroectodermal tumor family. J Clin Oncol 18(1):204–213PubMed

27.

Rossi S, Orvieto E, Furlanetto A et al (2004) Utility of the immunohistochemical detection of FLI-1 expression in round cell and vascular neoplasm using a monoclonal antibody. Mod Pathol 17(5):547–552PubMedCrossRef

28.

Thorner P, Squire J, Chilton-MacNeill S et al (1996) Is the EWS/FLI-1 fusion transcript specific for ewing sarcoma and peripheral primitive neuroectodermal tumor?: a report of four cases showing this transcript in a wider range of tumor types. Am J Pathol 148(4):1125–1138PubMed

29.

Park YK, Chi SG, Park HR et al (1998) Detection of t(11;22)(q24;q12) translocation of ewing’s sarcoma in paraffin embedded tissue by nested reverse transcription- polymerase chain reaction. J Korean Med Sci 13(4):395–399PubMed

30.

Ginsberg JP, De Alava E, Ladanyi M et al (1999) EWS-FLI1 and EWS-ERG gene fusions are associated with similar clinical phenotypes in ewing’s sarcoma. J Clin Oncol 17(6):1809–1814PubMed

31.

Qian X, Jin L, Shearer BM et al (2005) Molecular diagnosis of ewing’s sarcoma/primitive neuroectodermal tumor in formalin-fixed paraffin-embedded tissues by RT-PCR and fluorescence in situ hybridization. Diagn Mol Pathol 14(1):23–28PubMedCrossRef

Titel: The Evaluation of CD99 Immunoreactivity and EWS/FLI1 Translocation by Fluorescence in situ Hybridization in Central PNETs and Ewing’s Sarcoma Family of Tumors
verfasst von: Çiğdem Vural
Ömer Uluoğlu
Nalan Akyürek
Aynur Oğuz
Ceyda Karadeniz
Publikationsdatum: 01.09.2011
Verlag: Springer Netherlands
Erschienen in: Pathology & Oncology Research / Ausgabe 3/2011
Print ISSN: 1219-4956
Elektronische ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-010-9358-3

Springer Medizin

The Evaluation of CD99 Immunoreactivity and EWS/FLI1 Translocation by Fluorescence in situ Hybridization in Central PNETs and Ewing’s Sarcoma Family of Tumors

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2011

Primary Peritoneal Serous Papillary Carcinoma: A Clinical and Pathological Study

Clinical and Prognostic Value of the Presence of Irregular Giant Nuclear Cells in pT1 Ovarian Clear Cell Carcinoma

Downregulated Expression of Inhibitor of Growth 4 (ING4) in Advanced Colorectal Cancers: A Non-Randomized Experimental Study

Association of mtDNA D-Loop Polymorphisms with Risk of Gastric Cancer in Chinese Population

B-Raf Mutations, Microsatellite Instability and p53 Protein Expression in Sporadic Basal Cell Carcinomas

Estrogen Receptor Negative and Progesterone Receptor Positive Breast Carcinomas—How Frequent are they?

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie